Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
Background: Weused a sensitive and specific beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) assay to determine the relationship between BACE1 activity in cerebrospinal fluid (CSF) and markers of APP metabolism and axonal degeneration in early and late stages of Alzheimer disease (AD). Objective: To assess CSF BACE1 activity in AD. Design: Case-control and longitudinal follow-up